📊 HALO Key Takeaways
Is Halozyme Therapeutics, Inc.. (HALO) a Good Investment?
HaloZyme demonstrates strong 37.6% YoY revenue growth and exceptional free cash flow generation, but the 28.6% YoY decline in net income despite higher revenues indicates deteriorating earnings quality. The dangerously elevated 8.81x debt-to-equity ratio combined with an unsustainable 1.6% gross margin signals fundamental business model challenges and elevated financial risk.
Revenue growth is strong and operating profitability with exceptional free cash flow conversion supports balance sheet flexibility despite heavy leverage. Liquidity and interest coverage are robust, though the YoY earnings decline and anomalously low gross margin signal mix/accounting volatility to monitor.
Why Buy Halozyme Therapeutics, Inc.. Stock? HALO Key Strengths
- Strong revenue growth of 37.6% YoY with $376.7M in sales
- Exceptional free cash flow generation of $176.3M with 46.8% FCF margin demonstrating strong cash conversion
- Robust liquidity and interest coverage with 2.76x current ratio and 40.9x interest coverage ratio
- Strong top-line growth (+37.6% YoY) with high operating margin (33.6%)
- Exceptional free cash flow (46% margin) with minimal capex needs
- Solid liquidity (4.66x current) and very high interest coverage (104x)
HALO Stock Risks: Halozyme Therapeutics, Inc.. Investment Risks
- Net income declined 28.6% YoY and EPS fell 25.4% despite strong revenue growth, indicating poor earnings quality and unsustainable business model
- Critically high debt-to-equity ratio of 8.81x ($1.9B debt vs. $219.6M equity) creates substantial financial leverage risk and limits operational flexibility
- Exceptionally low gross margin of 1.6% is unsustainable and suggests fundamental cost structure or competitive pressures that threaten long-term profitability
- High leverage and thin equity (Debt/Equity 43.9x) raise refinancing/covenant risk
- Net income and EPS down YoY despite growth, indicating margin/expense volatility
- Extremely low reported gross margin (0.4%) suggests mix or accounting anomalies that could compress profitability if persistent
Key Metrics to Watch
- Gross margin trend and revenue composition drivers - unsustainable 1.6% margin must improve
- Debt-to-equity ratio and long-term debt levels - 8.81x leverage is dangerously high for declining profitability
- Operating cash flow sustainability and net income recovery - critical divergence between top-line growth and bottom-line performance must reverse
- Free cash flow (FCF) margin
- Interest coverage
Halozyme Therapeutics, Inc.. (HALO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 46.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.76x current ratio provides a solid financial cushion.
HALO Profit Margin, ROE & Profitability Analysis
HALO vs Healthcare Sector: How Halozyme Therapeutics, Inc.. Compares
How Halozyme Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Halozyme Therapeutics, Inc.. Stock Overvalued? HALO Valuation Analysis 2026
Based on fundamental analysis, Halozyme Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Halozyme Therapeutics, Inc.. Balance Sheet: HALO Debt, Cash & Liquidity
HALO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Halozyme Therapeutics, Inc..'s revenue has grown significantly by 215% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.10 reflects profitable operations.
HALO Revenue Growth, EPS Growth & YoY Performance
HALO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $264.9M | $118.1M | $0.93 |
| Q3 2025 | $290.1M | $137.0M | $1.05 |
| Q2 2025 | $231.4M | $93.2M | $0.72 |
| Q1 2025 | $195.9M | $76.8M | $0.60 |
| Q3 2024 | $216.0M | $81.8M | $0.61 |
| Q2 2024 | $221.0M | $74.8M | $0.56 |
| Q1 2024 | $162.1M | $39.6M | $0.29 |
| Q3 2023 | $209.0M | $61.6M | $0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Halozyme Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
HALO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Halozyme Therapeutics, Inc.. (CIK: 0001159036)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HALO
What is the AI rating for HALO?
Halozyme Therapeutics, Inc.. (HALO) has a Combined AI Rating of HOLD from Claude (SELL) and ChatGPT (BUY) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HALO's key strengths?
Claude: Strong revenue growth of 37.6% YoY with $376.7M in sales. Exceptional free cash flow generation of $176.3M with 46.8% FCF margin demonstrating strong cash conversion. ChatGPT: Strong top-line growth (+37.6% YoY) with high operating margin (33.6%). Exceptional free cash flow (46% margin) with minimal capex needs.
What are the risks of investing in HALO?
Claude: Net income declined 28.6% YoY and EPS fell 25.4% despite strong revenue growth, indicating poor earnings quality and unsustainable business model. Critically high debt-to-equity ratio of 8.81x ($1.9B debt vs. $219.6M equity) creates substantial financial leverage risk and limits operational flexibility. ChatGPT: High leverage and thin equity (Debt/Equity 43.9x) raise refinancing/covenant risk. Net income and EPS down YoY despite growth, indicating margin/expense volatility.
What is HALO's revenue and growth?
Halozyme Therapeutics, Inc.. reported revenue of $376.7M.
Does HALO pay dividends?
Halozyme Therapeutics, Inc.. does not currently pay dividends.
Where can I find HALO SEC filings?
Official SEC filings for Halozyme Therapeutics, Inc.. (CIK: 0001159036) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HALO's EPS?
Halozyme Therapeutics, Inc.. has a diluted EPS of $1.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HALO a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Halozyme Therapeutics, Inc.. has a HOLD rating with 64% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HALO stock overvalued or undervalued?
Valuation metrics for HALO: ROE of 68.3% (sector avg: 15%), net margin of 39.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy HALO stock in 2026?
Our dual AI analysis gives Halozyme Therapeutics, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is HALO's free cash flow?
Halozyme Therapeutics, Inc..'s operating cash flow is $180.1M, with capital expenditures of $3.7M. FCF margin is 46.8%.
How does HALO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 39.8% (avg: 12%), ROE 68.3% (avg: 15%), current ratio 2.76 (avg: 2).
Is Halozyme Therapeutics, Inc.. carrying too much debt?
HALO has a debt-to-equity ratio of 8.81x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.76 suggests adequate short-term liquidity.
Why is HALO's return on equity (ROE) so high?
Halozyme Therapeutics, Inc.. has a return on equity of 68.3%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 39.8% net margin.